Medacta Hits Data, Milestone Home Run

Medacta International, Inc. has announced new data and new milestones following the 8th M.O.R.E. International Symposium, a clinical educational meeting in Lugano, Switzerland.

According to the May 19, 2016 news release, new clinical results of Medacta’s AMIStem hip implant from a multi-center study found the five-year survival rate of AMIStem implants to be 97.75%. Another study presented at the symposium compared the clinical and radiologic outcomes of Medacta’s CT-based MyKnee instrumentation, a system of patient-matched cutting blocks that personalizes total knee replacement (TKR) procedures through preoperative 3D planning based on each patient’s unique anatomy. In this specific study of 222 consecutive total knee arthroplasties, patients from the MyKnee study group saw a significant improvement in Knee Society Function score and Visual Analog Score pain score compared to patients in the conventional instrument group.

Another study presented at the symposium highlighted the clinical results of Medacta’s GMK Sphere total knee replacement from a multi-center study that followed 280 patients receiving a GMK Sphere knee replacement from 8 different surgeons. Richard Field, M.D., professor of orthopedic surgery at St George’s University of London, concluded that the overall GMK Sphere revision rate was consistent with ODEP (Orthopaedic Data Evaluation Panel) criteria and that the improvement in patient outcome scores with GMK Sphere at one and three years compared favorably against other ODEP-rated implant designs.

A study authored by Professor Claudio Lamartina, Head of Operational Spine Unit at the Istituto Ortopedico Galeazzi IRCCS in Milan, Italy, and presented at the symposium examined Medacta’s MySpine patient-matched pedicle screw placement guide in three cadaveric spine specimens operated on by three surgeons. Of 46 inserted screws eligible for assessment, 91.3% were fully inside the pedicle. The findings indicate pedicle screw placement with Medacta’s MySpine technology is highly accurate and should be investigated in larger in vivo studies.

Asked about the MORE Symposium, Francesco Siccardi, executive vice president of Medacta International, told OTW, “The feedback we received from the 8th M.O.R.E. International Symposium has been extremely positive, both from a scientific and logistical point of view.”

“Attending surgeons appreciated the educational opportunity to learn more about how implant design, techniques and patient-specific treatment are improving outcomes and patient satisfaction in the changing orthopedic space. Several surgeons said the meeting had exceeded their expectations and they were able to bring useful information back home with them to help their patients. We also received a lot of positive feedback on our efforts to bring the industry together. Attendees were able to meet other surgeons and professionals in their fields and many compared best practices, trends they’ve witnessed, and success and challenges they’ve faced, all while making new connections in the process. The overall feedback we’ve received has been fantastic, with the most frequent question being ‘When are you going do it again?!’”